Clinical appropriateness: A key factor in outcome measure selection: The 36 item short form health survey in multiple sclerosis

Journal of Neurology Neurosurgery and Psychiatry

Volumn 68, Issue 2, 2000, Pages 150-156

  Freeman, J A ^a   Hobart, J C ^a   Langdon, D W ^a   Thompson, A J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Multiple sclerosis; Quality of life; SF 36

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISABILITY; DISEASE SEVERITY; FEMALE; HEALTH STATUS; HEALTH SURVEY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RELIABILITY; SCORING SYSTEM; TREATMENT OUTCOME; WELLBEING;

ADULT; AGED; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENT CARE TEAM; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0034054297     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.68.2.150     Document Type: Article

References (40)

1. Paty DW, McFarland H. Magnetic resonance techniques to monitor the long term evolution of multiple sclerosis pathology and to monitor definitive clinical trials. J Neurol Neurosurg Psychiatry 1998;64(suppl 1):S47-51.
2. European Study Group on Interferon 1-b in Secondary Progressive Multiple Sclerosis. Placebo-controlled multicentre randomised trial of interferon 1-b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352: 1491-7.
3. Freeman JA, Langdon DW, Hobart JC, et al. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 1997;42:236-14.
4. Vickrey BG, Hays RD, Harooni R, et al. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995;4:187-206.
5. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47:129-39.
6. Sharrack B, Hughes, Soudain S, et al. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 1999;122:141-9.
7. Rothwell PM. Quality of life in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;65:433.
8. Whitaker JN, McFarland HF, Rudge P, et al. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47.
9. Hobart JC, Lamping DL, Thompson AJ. Evaluating neurological outcome measures: the bare essentials. J Neurol Neurosurg Psychiatry 1996;60:127-30.
10. Patrick DL, Deyo RA. Generic and disease specific measures in assessing health status and quality of life. Medical Care 1989;27(suppl 3):S17-32.
11. Brazier JE, Harper R, Jones NMB, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160-4.
12. Ware JE, Snow KK, KosinsKi M, et al. SF-36 Health survey: manual and interpretation guide. Boston, Massachusetts: The Health Institute, New England Medical Centre; 1993.
13. Jenkinson C, Coulter A, Wright L. Short form 36 (SF-36) health survey questionnaire: normative data for adults of working age. BMJ 1993;306:1437-44.
14. Hermann BP, Vickrey B, Hays RD, et al. A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 1996;25:113-18.
15. Freeman JA, Langdon DNV, Hobart JC, et al. Health-related quality of life in people with multiple sclerosis undergoing inpatient rehabilitation. Journal of Neurological Rehabilitation 1996;10:185-94.
16. Brunet DG, Hopman WH, Singer MA, et al. Measurement of health-related quality of life in multiple sclerosis patients. Can J Neurol Sci 1996;23:99-103.
17. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: part 2: quality of life. Can J Neurol Sci 1998;25:31-8.
18. Di Fabio RP, Choi T, Soderberg J, et al. Health related quality of life for patients with progressive multiple sclerosis: influence of rehabilitation. Phys Ther 1997;77:1704-16.
19. Freeman JA, Langdon DW, Hobart JC, et al. Inpatient rehabilitation in multiple sclerosis. Do the benefits carry over into the community ? Neurology 1999;52:50-6.
20. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
22. British Society of Rehabilitation Medicine. Multiple sclerosis (Working Party Report) London: Royal College of Physicians, 1993.
23. Granger CV, Cotter AC, Hamilton BB, et al. Functional assessment scales: a study of persons with multiple sclerosis. Arch Phys Med Rehabil 1990;71:870-5.
24. Ware JE, Kosinski M, Keller SD. SF-36 Physical and mental health summary scales: a user's manual, 2nd ed. Boston, Massachusetts: The Health Institute, New England Medical Centre, 1994.
25. Vickrey BG, Hays RD, Genovese BJ, et al. Comparison of a generic to disease-targeted health-related quality of life measures for multiple sclerosis. J Clin Epidemiol 1997;50: 557-69.
26. Harwood RH, Ebrahim S. Manual of the London handicap scale. University of Nottingham: Department of Health Care of the Elderly; 1995.
27. Dalos NP, Rabins PV, Brooks BP, et al. Disease activity and emotional state in multiple sclerosis. Ann Neurol 1983;13: 573-7.
28. Lykouras L, Adrachta D, Kalfakis N, et al. GHQ as an aid to detect mental disorders in neurological inpatients. Acta Psychiatr Scand 1996;9:3212-6.
29. SPSS. SPSS for Windows Version 7.5. Seattle: SPSS, 1996.
30. Van der Putten JMF, Hobart JC, Freeman JA, et al. Measuring change in disability following inpatient rehabilitation: comparison of the responsiveness of the Barthel index and the functional independence measure. J Neurol Neurosurg Psychiatry 1999;66:480-4.
31. Cronbach LJ, Meehl PE. Construct validity in psychological tests. Psychol Bull 1955;52:281-302.
32. Kazis L, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178-88.
33. Cohen J. Statistical power analysis for the behavioural sciences. London: Academic Press, 1977.
34. Holmes W, Shea J. Performance of a new HIV/AIDS-targeted qualify of life (HAT-QOL) instrument in asymptomatic seropositive individuals. Qual Life Res 1997;6:561-71.
35. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994;36:S6-11.
36. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular Interferon β-Ia for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
37. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of MS: final outcome of the randomised controlled trial. Neurology 1995;45:1277-85.
38. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47:129-39.
39. La Rocca N, Ritvo PG, Miller DM, et al. Quality of life assessment in multiple sclerosis clinical trials. In: Goodkin DE, Rudick RA, eds. Multiple sclerosis advances in clinical trial design, treatment and future perspectives. London: Springer Verlag, 1996:145-61.
40. Lankhorst G, Jelles F, Smits, et al. Quality of life in multiple sclerosis: the disability and impact profile (DIP). J Neurol 1996;243:469-74.